What’s the difference between Wegovy and Ozempic, and how are they prescribed in Europe?

Wegovy vs Ozempic explained: semaglutide dosing, approved indications, weight loss vs type 2 diabetes, side effects, and eligibility criteria.

In this episode, we compare Wegovy and Ozempic — both containing semaglutide — and clarify how they differ in licensing, dosing, and clinical use under EU medical guidance.

You’ll learn:

• The active ingredient (semaglutide) and how GLP-1 receptor agonists work

• Why Wegovy is approved for weight management and Ozempic for type 2 diabetes

• Differences in maximum dosing and titration schedules

• Typical side effects such as nausea, vomiting, and gastrointestinal discomfort

• BMI thresholds and metabolic criteria used in eligibility assessment

• Contraindications, including certain endocrine conditions

• Situations where a prescription request may be declined pending blood tests or specialist review

We explain how doctors assess BMI, HbA1c, cardiovascular risk, medication history, and contraindications during an online consultation in the EU. Although both medications contain semaglutide, they are not interchangeable without medical review.

This episode reflects the clinical standards used by Mobi Doctor, where metabolic and weight management consultations are reviewed by a registered physician in line with EU prescribing guidance.

Read the full guide and transcript here:

https://www.mobidoctor.eu/blog/wegovy-vs-ozempic-whats-the-difference